vs

Side-by-side financial comparison of Mission Produce, Inc. (AVO) and Enovis CORP (ENOV). Click either name above to swap in a different company.

Enovis CORP is the larger business by last-quarter revenue ($548.9M vs $319.0M, roughly 1.7× Mission Produce, Inc.). Mission Produce, Inc. runs the higher net margin — 5.0% vs -104.1%, a 109.1% gap on every dollar of revenue. On growth, Enovis CORP posted the faster year-over-year revenue change (-2.2% vs -10.0%). Mission Produce, Inc. produced more free cash flow last quarter ($55.6M vs $29.1M). Over the past eight quarters, Mission Produce, Inc.'s revenue compounded faster (11.0% CAGR vs 9.8%).

Produce Co., Ltd. was a Japanese video game company. Founded on April 6, 1990 by former Irem employees, it developed a number of games for both Enix and Hudson Soft. Produce! have created games for arcades and for the Super Nintendo Entertainment System, Nintendo 64, PlayStation, and PC Engine systems.

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.

AVO vs ENOV — Head-to-Head

Bigger by revenue
ENOV
ENOV
1.7× larger
ENOV
$548.9M
$319.0M
AVO
Growing faster (revenue YoY)
ENOV
ENOV
+7.8% gap
ENOV
-2.2%
-10.0%
AVO
Higher net margin
AVO
AVO
109.1% more per $
AVO
5.0%
-104.1%
ENOV
More free cash flow
AVO
AVO
$26.5M more FCF
AVO
$55.6M
$29.1M
ENOV
Faster 2-yr revenue CAGR
AVO
AVO
Annualised
AVO
11.0%
9.8%
ENOV

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AVO
AVO
ENOV
ENOV
Revenue
$319.0M
$548.9M
Net Profit
$16.0M
$-571.1M
Gross Margin
17.5%
59.9%
Operating Margin
8.8%
-101.7%
Net Margin
5.0%
-104.1%
Revenue YoY
-10.0%
-2.2%
Net Profit YoY
-7.5%
18.8%
EPS (diluted)
$0.23
$-9.99

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVO
AVO
ENOV
ENOV
Q4 25
$319.0M
$548.9M
Q3 25
$357.7M
$564.5M
Q2 25
$380.3M
$558.8M
Q1 25
$334.2M
Q4 24
$354.4M
$561.0M
Q3 24
$324.0M
$505.2M
Q2 24
$297.6M
$525.2M
Q1 24
$258.7M
$516.3M
Net Profit
AVO
AVO
ENOV
ENOV
Q4 25
$16.0M
$-571.1M
Q3 25
$14.7M
$-36.7M
Q2 25
$3.1M
$-56.0M
Q1 25
$3.9M
Q4 24
$17.3M
$-703.2M
Q3 24
$12.4M
$-31.5M
Q2 24
$7.0M
$-18.6M
Q1 24
$0
$-72.0M
Gross Margin
AVO
AVO
ENOV
ENOV
Q4 25
17.5%
59.9%
Q3 25
12.6%
59.3%
Q2 25
7.5%
59.5%
Q1 25
9.4%
Q4 24
15.7%
54.8%
Q3 24
11.4%
56.7%
Q2 24
10.4%
55.0%
Q1 24
11.1%
57.7%
Operating Margin
AVO
AVO
ENOV
ENOV
Q4 25
8.8%
-101.7%
Q3 25
5.9%
-3.0%
Q2 25
1.8%
-8.4%
Q1 25
2.8%
Q4 24
8.1%
-118.5%
Q3 24
5.2%
-6.3%
Q2 24
4.1%
-8.4%
Q1 24
3.1%
-6.8%
Net Margin
AVO
AVO
ENOV
ENOV
Q4 25
5.0%
-104.1%
Q3 25
4.1%
-6.5%
Q2 25
0.8%
-10.0%
Q1 25
1.2%
Q4 24
4.9%
-125.4%
Q3 24
3.8%
-6.2%
Q2 24
2.4%
-3.5%
Q1 24
-13.9%
EPS (diluted)
AVO
AVO
ENOV
ENOV
Q4 25
$0.23
$-9.99
Q3 25
$0.21
$-0.64
Q2 25
$0.04
$-0.98
Q1 25
$0.05
Q4 24
$0.25
$-12.69
Q3 24
$0.17
$-0.58
Q2 24
$0.10
$-0.34
Q1 24
$0.00
$-1.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVO
AVO
ENOV
ENOV
Cash + ST InvestmentsLiquidity on hand
$64.8M
$33.6M
Total DebtLower is stronger
$95.8M
$1.4B
Stockholders' EquityBook value
$587.3M
$2.0B
Total Assets
$983.0M
$4.4B
Debt / EquityLower = less leverage
0.16×
0.67×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVO
AVO
ENOV
ENOV
Q4 25
$64.8M
$33.6M
Q3 25
$43.7M
$44.1M
Q2 25
$36.7M
$38.5M
Q1 25
$40.1M
Q4 24
$58.0M
$48.2M
Q3 24
$49.5M
$35.4M
Q2 24
$46.2M
$35.0M
Q1 24
$39.9M
$66.3M
Total Debt
AVO
AVO
ENOV
ENOV
Q4 25
$95.8M
$1.4B
Q3 25
$131.5M
$1.4B
Q2 25
$147.2M
$1.4B
Q1 25
$117.9M
Q4 24
$113.7M
$1.3B
Q3 24
$134.4M
$1.3B
Q2 24
$170.2M
$1.3B
Q1 24
$156.1M
$1.3B
Stockholders' Equity
AVO
AVO
ENOV
ENOV
Q4 25
$587.3M
$2.0B
Q3 25
$568.7M
$2.6B
Q2 25
$552.3M
$2.6B
Q1 25
$550.8M
Q4 24
$547.3M
$2.6B
Q3 24
$527.3M
$3.3B
Q2 24
$513.3M
$3.3B
Q1 24
$505.1M
$3.3B
Total Assets
AVO
AVO
ENOV
ENOV
Q4 25
$983.0M
$4.4B
Q3 25
$1.0B
$5.0B
Q2 25
$1.0B
$4.9B
Q1 25
$997.8M
Q4 24
$971.5M
$4.7B
Q3 24
$959.9M
$5.6B
Q2 24
$966.9M
$5.4B
Q1 24
$937.5M
$5.5B
Debt / Equity
AVO
AVO
ENOV
ENOV
Q4 25
0.16×
0.67×
Q3 25
0.23×
0.54×
Q2 25
0.27×
0.53×
Q1 25
0.21×
Q4 24
0.21×
0.52×
Q3 24
0.25×
0.40×
Q2 24
0.33×
0.41×
Q1 24
0.31×
0.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVO
AVO
ENOV
ENOV
Operating Cash FlowLast quarter
$67.2M
$82.6M
Free Cash FlowOCF − Capex
$55.6M
$29.1M
FCF MarginFCF / Revenue
17.4%
5.3%
Capex IntensityCapex / Revenue
3.6%
9.7%
Cash ConversionOCF / Net Profit
4.20×
TTM Free Cash FlowTrailing 4 quarters
$37.2M
$22.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVO
AVO
ENOV
ENOV
Q4 25
$67.2M
$82.6M
Q3 25
$34.4M
$47.8M
Q2 25
$-11.8M
$-1.6M
Q1 25
$-1.2M
Q4 24
$38.0M
$88.3M
Q3 24
$42.5M
$53.6M
Q2 24
$3.4M
$7.8M
Q1 24
$9.5M
$-36.2M
Free Cash Flow
AVO
AVO
ENOV
ENOV
Q4 25
$55.6M
$29.1M
Q3 25
$22.6M
$3.4M
Q2 25
$-25.0M
$-44.9M
Q1 25
$-16.0M
Q4 24
$31.1M
$35.1M
Q3 24
$34.9M
$2.4M
Q2 24
$-4.4M
$-31.6M
Q1 24
$-400.0K
$-73.1M
FCF Margin
AVO
AVO
ENOV
ENOV
Q4 25
17.4%
5.3%
Q3 25
6.3%
0.6%
Q2 25
-6.6%
-8.0%
Q1 25
-4.8%
Q4 24
8.8%
6.3%
Q3 24
10.8%
0.5%
Q2 24
-1.5%
-6.0%
Q1 24
-0.2%
-14.2%
Capex Intensity
AVO
AVO
ENOV
ENOV
Q4 25
3.6%
9.7%
Q3 25
3.3%
7.9%
Q2 25
3.5%
7.7%
Q1 25
4.4%
Q4 24
1.9%
9.5%
Q3 24
2.3%
10.1%
Q2 24
2.6%
7.5%
Q1 24
3.8%
7.2%
Cash Conversion
AVO
AVO
ENOV
ENOV
Q4 25
4.20×
Q3 25
2.34×
Q2 25
-3.81×
Q1 25
-0.31×
Q4 24
2.20×
Q3 24
3.43×
Q2 24
0.49×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVO
AVO

Avocado$256.9M81%
Blueberry$36.5M11%
Mango$18.7M6%
Other$6.9M2%

ENOV
ENOV

Reconstructive Segment$258.0M47%
Surgical$129.0M23%
Prevention And Recovery$92.6M17%
Other Prevention And Recovery$71.4M13%

Related Comparisons